PL2301962T3 - Wynalazek dotyczący glp-1 i eksendyny - Google Patents

Wynalazek dotyczący glp-1 i eksendyny

Info

Publication number: PL2301962T3
Authority: PL; Poland
Prior art keywords: glu; ser; gly; leu; ala
Prior art date: 2004-09-03

Application number

PL10012756T

Other languages

English (en)

Inventor

Marti Béhé

Thomas Behr

Martin Gotthardt

Burkhard Göke

Original Assignee

Philipps Univ Marburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-03

Filing date

2005-08-26

Publication date

2014-05-30

2005-08-26 Application filed by Philipps Univ Marburg filed Critical Philipps Univ Marburg

2014-05-30 Publication of PL2301962T3 publication Critical patent/PL2301962T3/pl

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 abstract 2
108010011459 Exenatide Proteins 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
108091006116 chimeric peptides Proteins 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
108010015174 exendin 3 Proteins 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Optics & Photonics (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)

PL10012756T 2004-09-03 2005-08-26 Wynalazek dotyczący glp-1 i eksendyny PL2301962T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE102004043153A DE102004043153B4 (de)	2004-09-03	2004-09-03	Erfindung betreffend GLP-1 und Exendin
EP10012756.2A EP2301962B1 (de)	2004-09-03	2005-08-26	Erfindung betreffend GLP-1 und Exendin
EP05778889A EP1784422B1 (de)	2004-09-03	2005-08-26	Erfindung betreffend glp-1 und exendin

Publications (1)

Publication Number	Publication Date
PL2301962T3 true PL2301962T3 (pl)	2014-05-30

Family

ID=35970651

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10012756T PL2301962T3 (pl)	2004-09-03	2005-08-26	Wynalazek dotyczący glp-1 i eksendyny
PL08020703T PL2070946T3 (pl)	2004-09-03	2005-08-26	Wynalazek dotyczący GLP-1 i eksendyny

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL08020703T PL2070946T3 (pl)	2004-09-03	2005-08-26	Wynalazek dotyczący GLP-1 i eksendyny

Country Status (16)

Country	Link
US (2)	US8268781B2 (pl)
EP (3)	EP2070946B1 (pl)
JP (1)	JP5047795B2 (pl)
KR (1)	KR101237152B1 (pl)
CN (3)	CN102358752B (pl)
AT (1)	ATE486090T1 (pl)
AU (1)	AU2005279537C1 (pl)
BR (1)	BRPI0515624A (pl)
CA (2)	CA2578252A1 (pl)
DE (2)	DE102004043153B4 (pl)
HR (1)	HRP20110061T1 (pl)
MX (1)	MX2007002455A (pl)
NO (1)	NO20071592L (pl)
PL (2)	PL2301962T3 (pl)
RU (3)	RU2489443C2 (pl)
WO (1)	WO2006024275A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007013655A (es) *	2005-05-05	2008-01-24	Cadila Healthcare Ltd	Nuevos compuestos como agonistas glp-i.
EP2818181B1 (en)	2007-01-08	2018-10-24	The Trustees Of The University Of Pennsylvania	Compositions and medical uses thereof
WO2010032509A1 (ja) *	2008-09-20	2010-03-25	国立大学法人京都大学	膵島イメージング用分子プローブ前駆体及びその使用
EP3228320B1 (de)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
US8992886B2 (en)	2009-04-06	2015-03-31	Board Of Regents, The University Of Texas System	Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
JP5685401B2 (ja) *	2009-08-10	2015-03-18	国立大学法人京都大学	膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
WO2011027584A1 (ja) *	2009-09-04	2011-03-10	国立大学法人京都大学	膵島イメージング用分子プローブ及びその使用
JP5608867B2 (ja) *	2009-09-30	2014-10-15	国立大学法人京都大学	膵島イメージング用分子プローブ及びその使用
PT2554183T (pt)	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es)	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
EP2510951B1 (en)	2009-12-10	2016-07-13	Kyoto University	Molecular probe for imaging of pancreatic islet, and use thereof
CN101875700B (zh) *	2010-04-09	2012-09-26	无锡和邦生物科技有限公司	一种增加促胰岛素分泌肽融合蛋白生物活性的方法
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9278146B2 (en)	2010-10-08	2016-03-08	Kyoto University	Peptide derivative and use of the same
US9289516B2 (en)	2011-03-09	2016-03-22	The General Hospital Corporation	Imaging beta cell mass
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9944687B2 (en)	2011-07-04	2018-04-17	Imperial Innovations Limited	Compounds and their effects on feeding behaviour
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) *	2012-04-27	2014-12-02	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) *	2012-04-27	2013-12-12	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) *	2012-12-11	2019-10-11	英商梅迪繆思有限公司	用於治療肥胖之升糖素與glp-1共促效劑
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
CN103344764B (zh) *	2013-06-19	2014-11-26	天津美德太平洋科技有限公司	胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de)	2014-09-04	2016-03-10	Eberhard Karls Universität Tübingen Medizinische Fakultät	Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
RS62368B1 (sr)	2015-05-22	2021-10-29	Univ Leland Stanford Junior	Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
RU2018125958A (ru)	2015-12-14	2020-01-20	Санофи	Селективные агонисты рецептора глюкагона, содержащие хелатообразующий фрагмент, для целей визуализации
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
BR112019010236A2 (pt)	2016-11-21	2019-08-20	Eiger Biopharmaceuticals, Inc	formulações tamponadas de exendina (9-39)
JP7736315B2 (ja)	2020-03-31	2025-09-09	アンタロスメディカルアクティエボラーグ	イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0436005T3 (da)	1989-07-20	1995-07-03	Sandoz Ltd	Mærkede polypeptidderivater
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) *	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
JP2000516912A (ja) *	1996-06-05	2000-12-19	ロシュダイアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
AU2610599A (en) *	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
AU3247799A (en) *	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
CN1495198A (zh) *	1998-12-07	2004-05-12	�о��Ӧ�ÿ�ѧЭ��ɷ��޹�˾	胰高血糖素样肽-1的类似物
CN1372570A (zh) *	1999-04-30	2002-10-02	安米林药品公司	修饰的exendin和exendin激动剂
SI1105409T1 (sl) *	1999-05-17	2006-06-30	Conjuchem Inc	Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
EP1180121B9 (en) *	1999-05-17	2004-09-08	Conjuchem, Inc.	Long lasting insulinotropic peptides
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
JP2003519667A (ja) *	2000-01-10	2003-06-24	アミリン・ファーマシューティカルズ，インコーポレイテッド	トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
US7514078B2 (en) *	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
PL377591A1 (pl) *	2002-10-02	2006-02-06	Zealand Pharma A/S	Stabilizowane związki eksendyny-4
CN100354306C (zh) *	2002-10-11	2007-12-12	株式会社三和化学研究所	Glp－1衍生物及其经粘膜吸收的制剂

2004
- 2004-09-03 DE DE102004043153A patent/DE102004043153B4/de not_active Expired - Fee Related
2005
- 2005-08-26 CN CN201110114845.XA patent/CN102358752B/zh not_active Expired - Fee Related
- 2005-08-26 BR BRPI0515624-6A patent/BRPI0515624A/pt not_active IP Right Cessation
- 2005-08-26 RU RU2010148447/10A patent/RU2489443C2/ru not_active IP Right Cessation
- 2005-08-26 PL PL10012756T patent/PL2301962T3/pl unknown
- 2005-08-26 EP EP08020703.8A patent/EP2070946B1/de not_active Expired - Lifetime
- 2005-08-26 EP EP05778889A patent/EP1784422B1/de not_active Expired - Lifetime
- 2005-08-26 CN CN2005800297604A patent/CN101010340B/zh not_active Expired - Fee Related
- 2005-08-26 CN CN2011101471272A patent/CN102304179A/zh active Pending
- 2005-08-26 KR KR1020077007577A patent/KR101237152B1/ko not_active Expired - Fee Related
- 2005-08-26 RU RU2007112115/10A patent/RU2420536C2/ru not_active IP Right Cessation
- 2005-08-26 CA CA002578252A patent/CA2578252A1/en not_active Abandoned
- 2005-08-26 AT AT05778889T patent/ATE486090T1/de active
- 2005-08-26 PL PL08020703T patent/PL2070946T3/pl unknown
- 2005-08-26 EP EP10012756.2A patent/EP2301962B1/de not_active Expired - Lifetime
- 2005-08-26 HR HR20110061T patent/HRP20110061T1/hr unknown
- 2005-08-26 DE DE502005010449T patent/DE502005010449D1/de not_active Expired - Lifetime
- 2005-08-26 WO PCT/DE2005/001503 patent/WO2006024275A2/de not_active Ceased
- 2005-08-26 CA CA2797666A patent/CA2797666A1/en not_active Abandoned
- 2005-08-26 JP JP2007528593A patent/JP5047795B2/ja not_active Expired - Fee Related
- 2005-08-26 MX MX2007002455A patent/MX2007002455A/es active IP Right Grant
- 2005-08-26 AU AU2005279537A patent/AU2005279537C1/en not_active Ceased
2007
- 2007-03-02 US US11/712,978 patent/US8268781B2/en not_active Expired - Fee Related
- 2007-03-27 NO NO20071592A patent/NO20071592L/no not_active Application Discontinuation
2010
- 2010-11-26 RU RU2010148446/10A patent/RU2486197C2/ru not_active IP Right Cessation
2012
- 2012-08-24 US US13/593,866 patent/US20130095037A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2797666A1 (en)	2006-03-09
KR20070093960A (ko)	2007-09-19
DE102004043153B4 (de)	2013-11-21
HRP20110061T1 (hr)	2011-02-28
BRPI0515624A (pt)	2008-07-29
AU2005279537B2 (en)	2012-02-16
CN101010340A (zh)	2007-08-01
EP2301962A3 (de)	2011-11-02
DE502005010449D1 (de)	2010-12-09
CN101010340B (zh)	2012-11-28
JP5047795B2 (ja)	2012-10-10
CA2578252A1 (en)	2006-03-09
JP2008511557A (ja)	2008-04-17
KR101237152B1 (ko)	2013-03-04
EP2301962B1 (de)	2013-10-30
RU2489443C2 (ru)	2013-08-10
PL2070946T3 (pl)	2013-09-30
RU2420536C2 (ru)	2011-06-10
RU2010148447A (ru)	2012-06-10
WO2006024275A2 (de)	2006-03-09
AU2005279537C1 (en)	2012-07-05
MX2007002455A (es)	2007-10-10
RU2486197C2 (ru)	2013-06-27
CN102304179A (zh)	2012-01-04
US20090180953A1 (en)	2009-07-16
EP2070946A2 (de)	2009-06-17
RU2007112115A (ru)	2008-10-10
CN102358752A (zh)	2012-02-22
EP1784422A2 (de)	2007-05-16
EP2070946B1 (de)	2013-05-29
WO2006024275A3 (de)	2006-11-30
US20130095037A1 (en)	2013-04-18
DE102004043153A1 (de)	2006-03-23
CN102358752B (zh)	2014-07-30
AU2005279537A1 (en)	2006-03-09
EP1784422B1 (de)	2010-10-27
ATE486090T1 (de)	2010-11-15
US8268781B2 (en)	2012-09-18
RU2010148446A (ru)	2012-06-10
NO20071592L (no)	2007-05-29
EP2301962A2 (de)	2011-03-30
EP2070946A3 (de)	2009-09-09

Publication	Publication Date	Title
PL2301962T3 (pl)	2014-05-30	Wynalazek dotyczący glp-1 i eksendyny
AR131857A2 (es)	2025-05-07	Compuestos co-agonistas de gip y glp-1
JOP20250198A1 (ar)	2025-08-03	مركبات مساعدة مشتركة gip/glp1
JOP20230077A1 (ar)	2023-04-16	محفزات glp 1/ gip مزدوجة
RU2019122785A (ru)	2021-01-22	Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
EA200800699A1 (ru)	2008-10-30	Слитые полипептиды, содержащие glp-1 (глюкагонподобный пептид-1), с повышенной устойчивостью к пептидазам
NO20063436L (no)	2006-08-25	Intranasal administrasjon av glukose-regulerende peptider
JOP20220344A1 (ar)	2022-12-20	عوامل مساعدة glp-1/gip مزدوجة ممتدة المفعول
RU2010101232A (ru)	2011-07-27	Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
MX2009002999A (es)	2009-04-01	Analogos de insulina resistentes a proteasa.
PE20231842A1 (es)	2023-11-21	Coagonistas de los receptores de glp-1 y gip
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
HRP20020996B1 (hr)	2011-09-30	Analozi peptida-1 nalik na glukagon
EA200300644A1 (ru)	2003-12-25	Слитые белки glp-1
WO2003058203A3 (en)	2007-02-01	Extended glucagon-like peptide-1 analogs
DK1523325T3 (da)	2011-11-21	Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
RU2012109553A (ru)	2013-09-20	Модифицированные вазоактивные интестинальные пептиды
WO2007028394A3 (en)	2007-09-20	Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
AU2017277594A1 (en)	2019-02-07	Protease-resistant mono-lipidated peptides
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
Kühn-Wache et al.	2000	Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance
Karas et al.	2013	Total chemical synthesis of a heterodimeric interchain bis‐lactam‐linked peptide: application to an analogue of human insulin‐like peptide 3
EA202092891A1 (ru)	2021-04-19	Соединения-коагонисты gip/glp1
TH2101000319A (th)	2025-06-30	สารประกอบอะโกนิสท์ร่วม gip/glp1